VERAXA Showcases BiTAC Platform At ASCO Annual Meeting And BIO International Convention, Prepares For NASDAQ Listing In 2025

VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager"))), announced today it will be attending the upcoming ASCO Annual Meeting and BIO International Convention.

At the conferences, Christoph Antz, CEO, and additional members of the VERAXA leadership team will be meeting with potential partners and investors, showcasing the Company's novel Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and sharing the Company's growth plans as it prepares to list on the NASDAQ later this year. VERAXA is leveraging its proprietary BiTAC platform to develop highly specific dual-target oncology therapies with less off-tumor toxicity and enhanced tumor specificity. The Company is currently pursuing nine discovery and development programs comprised of next-generation bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). Those wishing to schedule a meeting to learn more about VERAXA's differentiated technology and approach are encouraged to contact Cristoph Antz at antz@veraxa.com.

VERAXA will be accompanied by members of Voyager Acquisition Corp. as well as representatives from Cantor Fitzgerald, Voyager's recently retained capital markets advisor. Cantor Fitzgerald, a leading global financial services group, has agreed to provide certain capital markets advisory services to Voyager related to its proposed Business Combination with VERAXA.